Post by Biomed Valley Discoveries

May is #BrainTumorAwarenessMonth – a time dedicated to supporting and amplifying the voices of those facing brain cancer. At BVD, our brain cancer efforts are focused on advancing ulixertinib – our investigational, highly selective ERK 1/2 inhibitor – in adult and pediatric glioma. Gliomas are tumors that form in the brain or spinal cord. Some gliomas grow and spread slowly (low-grade) while others grow and spread quickly (high-grade). Gliomas can cause vision loss, difficulty walking or balancing, trouble speaking, personality changes, cognitive problems, seizures, and numbness. Many gliomas are life-threatening. Ulixertinib has shown potential in both adult and pediatric glioma across multiple mutations, including NF1, BRAF V600, and BRAF non-V600. It has also demonstrated the ability to penetrate the blood/brain barrier in adults with low-grade glioma. Along with our collaborators, we are advancing a clinical study of ulixertinib in adult patients impacted by both low- and high-grade glioma, and a pediatric low-grade glioma trial is expected to be initiated this year. Learn more about Brain Tumor Awareness Month: https://lnkd.in/eAkMq6vw #BrainCancer #BrainCancerAwarenessMonth #GrayMay #GoGrayInMay #BTAM #MAPK #ERKinhibition #LowGradeGlioma #HighGradeGlioma #HopeForLife

Video Content